Donor derived hepatitis B virus infection: Analysis of the Organ ProcurementTransplantation Network/United Network for Organ Sharing Ad Hoc Disease Transmission Advisory Committee
| Autor: | Aneesh K. Mehta, R. Patrick Wood, Ricardo M. La Hoz, Lynne Strasfeld, Kathleen Lilly, Gerald J. Berry, Chak Sum Ho, Remzi Bag, Marian G. Michaels, Diana F. Florescu, Nicole Theodoropoulos, Gabriel Vece, Lara Danziger-Isakov, Maricar Malinis, Cameron R. Wolfe, Michael A. Nalesnik, David S. Goldberg, Robert G. Sawyer, Jamie Bucio |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
HBsAg
Hepatitis B virus Tissue and Organ Procurement Advisory Committees Viremia 030230 surgery medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Antigen medicine Humans Hepatitis B Antibodies Transplantation Hepatitis B Surface Antigens biology Transmission (medicine) business.industry virus diseases Lamivudine medicine.disease Hepatitis B Virology Hepatitis B Core Antigens digestive system diseases Tissue Donors Infectious Diseases biology.protein 030211 gastroenterology & hepatology Antibody business medicine.drug |
| Zdroj: | Transplant infectious disease : an official journal of the Transplantation SocietyREFERENCES. 23(1) |
| ISSN: | 1399-3062 |
| Popis: | Hepatitis B virus (HBV) can be transmitted from organ donor to recipient, but details of transmission events are not widely published. The Disease Transmission Advisory Committee (DTAC) evaluated 105 cases of potential donor derived transmission events of HBV between 2009-2017. Proven, probable or possible transmission of HBV occurred in 25 (23.8%) cases. Recipients of liver grafts were most commonly infected (20 of 21 exposed recipients) compared to 9 of 21 exposed non-hepatic recipients. Eleven of 25 donors were HBV core antibody (HBcAb) positive/HBV surface antigen (HBsAg) negative and infected 8/20 recipients. Of the 10 liver recipients and 1 liver-kidney recipient who received organs from these donors: six were not given antiviral prophylaxis, two developed infection after antiviral prophylaxis was discontinued, two developed HBV while on lamivudine prophylaxis, one was on antiviral prophylaxis and did not develop HBV viremia or antigenemia. One recipient of a HBcAb positive/HBsAg negative kidney developed active HBV infection. Unexpected donor-derived transmission of HBV was a rare event in reports to DTAC, but was often detected in the recipient late post-transplant. Six of 11 recipients (54.5%) of a liver from a HBcAb positive donor did not receive prophylaxis; all of these were potentially preventable with the use of anti-viral prophylaxis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text